BCG vaccination curbs tau tangles in mice by boosting microglial cleanup, fueling hopes for human trials to reduce dementia risk.
|Slideshows|October 17, 2019
5 Psychopharmacologic Approaches to Treating Tinnitus
Author(s)Zeina Chemali, MD, MPH, Romy Nehme, MD
Tinnitus affects 50 million people in the US and can require urgent medical assistance. It can also cause considerable anxiety and even hallucinations. Reducing symptom intensity is key.
Advertisement
Advertisement
Related to this article
Neflamapimod misses its main DLB endpoint, but biomarker and subgroup signals suggest IL-1β pathway impact and may justify a phase 3 trial.
Cingulate shares plans to resubmit its ADHD candidate CTx-1301 to the FDA, following a CRL tied to CMC information requests
Digital memory tests flag subtle preclinical Alzheimer changes, especially with neocortical tau; scalable tools may boost future trial screening.
Why D2 blockade alone falls short in schizophrenia, and what neurotransmitter, genetic and neuroimaging research means for treatment-resistant patients.
GLP-1 drugs enter psychiatry, curbing antipsychotic weight gain while raising new questions about addiction, mood, eating disorders, and culture.
A Delphi panel recommends screening for eating disorders before GLP-1 receptor agonist initiation.
Alkermes launches a phase 2 trial of oral orexin-2 agonist ALKS 7290 to boost antidepressant response in major depressive disorder, assessing safety and symptom relief.
Advertisement
Advertisement
Trending on Psychiatric Times
1
Lumateperone Shows Significant and Rapid Improvement in Bipolar Mania
2
NDA Submission Complete: COMP360 Psilocybin for Treatment-Resistant Depression
3
New National Guidance for Managing Medetomidine Intoxication and Withdrawal
4
Updates on CTx-1301, NDA Resubmission After FDA Complete Response Letter
5